Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Buck Institute and Biotica Investigate Polyketides in Extension of Healthy Lifespan

15.09.2011
The Buck Institute for Research on Aging (Novato, CA) and Biotica Technology Ltd. (Cambridge, UK) today announced a three-year collaboration to investigate polyketides in diseases of aging.

Building on observations that rapamycin extends healthy lifespan in various species (Kaeberlein & Kennedy; Nature 2009), the collaborators will evaluate rapamycin analogs and other polyketides in a broad range of age-related disease models to identify novel therapeutics.

“We welcome this collaboration with Biotica with great enthusiasm. Their polyketides represent some of the most novel and promising drug leads for the development of therapeutics for age-related disease,” said Buck Institute CEO and President Brian Kennedy, PhD, who added that several Buck laboratories will be involved in the screening process. “We look forward to working with Biotica to move potential therapeutics toward commercialization. We have great respect for the company and their technology - the fact that we will both benefit from commercialization of new discoveries is a harbinger of great things to come.”

“Prof. Kennedy and the Buck Institute are recognized as leaders in research on aging, and have played a key role in identifying the life-extending properties of rapamycin,” commented Barrie Wilkinson, PhD, Biotica’s VP of Research. “We’re extremely fortunate to be working with the Buck’s outstanding investigators, and to have access to their diverse range of scientific approaches to age-related disease.”

The collaboration builds upon an existing relationship between Prof. Kennedy and Biotica, studying longevity-enhancing properties of non-rapamycin polyketides. The recent return of Biotica’s rapamycin analog program from Pfizer, in August 2011, has created an opportunity to add value in addition to its current focus on multiple sclerosis (MS) and systemic lupus erythematosus (SLE). In addition to the work on rapamycin analogs, the collaborators expect to identify new polyketides with therapeutic potential in age-related disease.

About the Buck Institute for Research on Aging
The Buck Institute is the first freestanding institute in the United States that is devoted solely to basic research on aging and age-associated disease. The Institute is an independent nonprofit organization dedicated to extending the healthspan, the healthy years of each individual’s life. Buck Institute scientists work in an innovative, interdisciplinary setting to understand the mechanisms of aging and to discover new ways of detecting, preventing and treating conditions such as Alzheimer’s and Parkinson’s disease, cancer, cardiovascular disease and stroke. Collaborative research at the Institute is supported by new developments in genomics, proteomics and bioinformatics technology. For additional information visit www.buckinstitute.org.
About Biotica Technology Limited
Biotica is a privately-held biotechnology company that discovers and develops polyketide therapeutics. It has a growing pipeline of novel therapeutic programs supported by clinical validation. These include nPT-mTOR (unique rapamycin analogs), nPT-CyP (cyclophilin inhibitors for HCV) and nPT-ery (anti-inflammatory erythromycin analogs partnered with GlaxoSmithKline). All of Biotica’s projects employ its proprietary novoPT™ technology, which enables it to select from the many known polyketides with biological activity and make a range of derivatives that are either difficult or impossible to make by medicinal chemistry methods. For additional information visit www.biotica.com.

Kris Rebillot | Newswise Science News
Further information:
http://www.buckinstitute.org

More articles from Life Sciences:

nachricht Scientists uncover the role of a protein in production & survival of myelin-forming cells
19.07.2018 | Advanced Science Research Center, GC/CUNY

nachricht NYSCF researchers develop novel bioengineering technique for personalized bone grafts
18.07.2018 | New York Stem Cell Foundation

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

A smart safe rechargeable zinc ion battery based on sol-gel transition electrolytes

20.07.2018 | Power and Electrical Engineering

Reversing cause and effect is no trouble for quantum computers

20.07.2018 | Information Technology

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern

20.07.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>